首页 > 最新文献

Orvosi hetilap最新文献

英文 中文
[Review of paraneoplastic retinopathies illustrated by two case reports]. [副肿瘤视网膜病变的回顾,附两例报告]。
IF 0.9 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-11-30 DOI: 10.1556/650.2025.33434
Hanna Barsi, Bernadett Fazekas, Zoltán Zsolt Nagy, Zsuzsanna Szepessy

The clinical symptoms of paraneoplastic syndromes affecting the retina are varied and difficult to recognize. Ocular symptoms often appear as the first symptom, even before the diagnosis of cancer, so their recognition is of great importance. In our paper, we discuss paraneoplastic syndromes affecting the retina: cancer-associated retinopathy, melanoma-associated retinopathy, paraneoplastic vitelliform maculopathy, paraneoplastic optic neuropathy, and bilateral diffuse uveal melanocyte proliferation with case reports. Our goal is to contribute to the early diagnosis and rapid, adequate treatment of cancer through the early detection of paraneoplastic ophthalmic syndromes and a multidisciplinary approach. Orv Hetil. 2025; 166(48): 1898-1907.

影响视网膜的副肿瘤综合征的临床症状多种多样,难以识别。眼部症状往往出现在癌症的第一症状,甚至在癌症的诊断之前,因此对眼部症状的识别是非常重要的。在我们的论文中,我们讨论了影响视网膜的副肿瘤综合征:癌症相关视网膜病变,黑色素瘤相关视网膜病变,副肿瘤黄斑病变,副肿瘤视神经病变和双侧弥漫性葡萄膜黑素细胞增殖的病例报告。我们的目标是通过早期发现副肿瘤眼科综合征和多学科方法,促进癌症的早期诊断和快速,充分的治疗。Orv Hetil. 2025;166(48): 1898 - 1907。
{"title":"[Review of paraneoplastic retinopathies illustrated by two case reports].","authors":"Hanna Barsi, Bernadett Fazekas, Zoltán Zsolt Nagy, Zsuzsanna Szepessy","doi":"10.1556/650.2025.33434","DOIUrl":"10.1556/650.2025.33434","url":null,"abstract":"<p><p>The clinical symptoms of paraneoplastic syndromes affecting the retina are varied and difficult to recognize. Ocular symptoms often appear as the first symptom, even before the diagnosis of cancer, so their recognition is of great importance. In our paper, we discuss paraneoplastic syndromes affecting the retina: cancer-associated retinopathy, melanoma-associated retinopathy, paraneoplastic vitelliform maculopathy, paraneoplastic optic neuropathy, and bilateral diffuse uveal melanocyte proliferation with case reports. Our goal is to contribute to the early diagnosis and rapid, adequate treatment of cancer through the early detection of paraneoplastic ophthalmic syndromes and a multidisciplinary approach. Orv Hetil. 2025; 166(48): 1898-1907.</p>","PeriodicalId":19911,"journal":{"name":"Orvosi hetilap","volume":"166 48","pages":"1898-1907"},"PeriodicalIF":0.9,"publicationDate":"2025-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145637487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Conceptual interpretations of healthcare quality]. [医疗保健质量的概念解释]。
IF 0.9 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-11-30 DOI: 10.1556/650.2025.33436
Zoltán Ónodi-Szűcs, János Sándor, Szilvia Vincze, Karolina Kósa

The study reviews the development of the concept of healthcare quality starting from its foundations in the second half of the 20th century. Donabedian's landmark publication in 1966 distinguished three dimensions - structure, process, outcome - into which all topics of healthcare quality can be allocated. Donabedian's groundwork expanded into an important field of research both in the United States and Europe. The conceptual foundations were further enriched by the introduction of the health system concept of the World Health Organization, and by the "Health Care Quality Indicators" project launched by the OECD in 2006. The development of quantitative indicators of healthcare quality, primarily those related to outcomes such as burden of disease enabled comparisons between diseases and across countries. The core characteristics of health care quality, showing the strongest relation to the desired outcome ("health") according to the updated concept of the OECD are effectiveness, safety, and patient-centeredness. Hungary did not participate in the OECD project on healthcare quality development, and patient-centeredness has not been included among the characteristics of healthcare quality in the country as opposed to effectiveness and safety. This is a disadvantage in healthcare financed by social insurance not only in terms of relevant indicators not being monitored but also in comparison to private providers of healthcare which are expressly patient-centered. Patient satisfaction monitored by some Hungarian institutions represents only one and not even the most important indicator of the complex concept of patient-centeredness. One of the future challenges for the Hungarian healthcare system is the development and international alignment of the concept of healthcare quality, since any outcome of a healthcare system can only be interpreted in light of the extent to which it ensured subjectively positive experiences for patients. Orv Hetil. 2025; 166(48): 1887-1897.

本研究回顾了20世纪下半叶医疗保健质量概念的发展历程。Donabedian于1966年出版的具有里程碑意义的出版物区分了结构、过程和结果三个维度,所有医疗保健质量的主题都可以分配到这三个维度中。多纳伯迪安的基础工作在美国和欧洲扩展成了一个重要的研究领域。世界卫生组织的卫生系统概念的引入和经合组织2006年发起的“卫生保健质量指标”项目进一步丰富了概念基础。制定医疗保健质量的量化指标,主要是那些与疾病负担等结果有关的指标,使疾病之间和国家之间能够进行比较。根据经合组织的最新概念,医疗保健质量的核心特征与预期结果(“健康”)的关系最为密切,这些特征是有效性、安全性和以患者为中心。匈牙利没有参加经合组织关于保健质量发展的项目,与有效性和安全性相反,以病人为中心并没有被列入该国保健质量的特征。这在社会保险资助的医疗保健方面是一个劣势,不仅因为相关指标不受监测,而且与明确以病人为中心的私营医疗保健提供者相比也是如此。匈牙利一些机构监测的患者满意度只是以患者为中心这一复杂概念的一个指标,甚至不是最重要的指标。匈牙利医疗保健系统未来面临的挑战之一是医疗保健质量概念的发展和国际一致性,因为医疗保健系统的任何结果只能根据它确保患者主观积极体验的程度来解释。Orv Hetil. 2025;166(48): 1887 - 1897。
{"title":"[Conceptual interpretations of healthcare quality].","authors":"Zoltán Ónodi-Szűcs, János Sándor, Szilvia Vincze, Karolina Kósa","doi":"10.1556/650.2025.33436","DOIUrl":"10.1556/650.2025.33436","url":null,"abstract":"<p><p>The study reviews the development of the concept of healthcare quality starting from its foundations in the second half of the 20th century. Donabedian's landmark publication in 1966 distinguished three dimensions - structure, process, outcome - into which all topics of healthcare quality can be allocated. Donabedian's groundwork expanded into an important field of research both in the United States and Europe. The conceptual foundations were further enriched by the introduction of the health system concept of the World Health Organization, and by the \"Health Care Quality Indicators\" project launched by the OECD in 2006. The development of quantitative indicators of healthcare quality, primarily those related to outcomes such as burden of disease enabled comparisons between diseases and across countries. The core characteristics of health care quality, showing the strongest relation to the desired outcome (\"health\") according to the updated concept of the OECD are effectiveness, safety, and patient-centeredness. Hungary did not participate in the OECD project on healthcare quality development, and patient-centeredness has not been included among the characteristics of healthcare quality in the country as opposed to effectiveness and safety. This is a disadvantage in healthcare financed by social insurance not only in terms of relevant indicators not being monitored but also in comparison to private providers of healthcare which are expressly patient-centered. Patient satisfaction monitored by some Hungarian institutions represents only one and not even the most important indicator of the complex concept of patient-centeredness. One of the future challenges for the Hungarian healthcare system is the development and international alignment of the concept of healthcare quality, since any outcome of a healthcare system can only be interpreted in light of the extent to which it ensured subjectively positive experiences for patients. Orv Hetil. 2025; 166(48): 1887-1897.</p>","PeriodicalId":19911,"journal":{"name":"Orvosi hetilap","volume":"166 48","pages":"1887-1897"},"PeriodicalIF":0.9,"publicationDate":"2025-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145637433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Chronic thromboembolic pulmonary hypertension - the hidden disease]. 慢性血栓栓塞性肺动脉高压——隐性疾病。
IF 0.9 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-11-30 DOI: 10.1556/650.2025.33433
Gábor Kolodzey, László Balogh, Judit Barta, Andrea Péter, Tibor Szűk

Introduction: Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but potentially curable form of pulmonary hypertension. Its pathophysiological background involves incomplete thrombus resolution following acute pulmonary embolism, in situ thrombosis, and vascular remodeling. An increase in pulmonary vascular resistance leads to persistent pulmonary hypertension, which, if left untreated, may progress to fatal right heart failure. CTEPH is often considered a "hidden" disease, as its nonspecific symptoms are frequently misattributed to other conditions.

Objective: To provide an update overview of the epidemiology, pathophysiology, diagnostic challenges, and therapeutic options of CTEPH, with particular emphasis on the role of the general practitioners and the internists in early recognition.

Method: A narrative literature review based on the 2022 ESC/ERS guidelines, the most recent European and international registries, and contemporary review.

Results: The incidence of CTEPH following pulmonary embolism is estimated at 2-4%, although its true prevalence is likely higher. Diagnostic delays are common, with patients typically presenting to pulmonary hypertension centers 18-24 months after symptom onset. Pulmonary endarterectomy offers a curative treatment option for patients with surgically accessible central lesions. For inoperable or residual CTEPH, balloon pulmonary angioplasty and targeted pharmacological therapy, such as riociguat, have opened new therapeutic perspectives.

Discussion: Diagnosis of CTEPH remains a complex challenge. General practitioners have a pivotal role by considering CTEPH in patients with recurrent dyspnea, exercise intolerance, signs of right heart failure, or persistent symptoms following pulmonary embolism, and by ensuring timely referral to specialized pulmonary hypertension centers.

Conclusion: Early diagnosis and evidence-based management of CTEPH can significantly improve both quality of life and survival. As general practitioners and internists are on the frontline, their awareness and education are crucial for early disease recognition. Orv Hetil. 2025; 166(48): 1908-1915.

慢性血栓栓塞性肺动脉高压(CTEPH)是一种罕见但有治愈潜力的肺动脉高压。其病理生理背景包括急性肺栓塞后血栓不完全溶解、原位血栓形成和血管重构。肺血管阻力增加导致持续性肺动脉高压,如果不及时治疗,可能发展为致命的右心衰。CTEPH通常被认为是一种“隐藏的”疾病,因为它的非特异性症状经常被误认为是其他疾病。目的:提供关于CTEPH的流行病学、病理生理学、诊断挑战和治疗选择的最新概述,特别强调全科医生和内科医生在早期识别中的作用。方法:基于2022年ESC/ERS指南,最新的欧洲和国际注册,以及当代综述的叙述性文献综述。结果:肺栓塞后CTEPH的发生率估计为2-4%,尽管其真实患病率可能更高。诊断延迟是常见的,患者通常在症状出现后18-24个月出现在肺动脉高压中心。肺内膜切除术为手术可及的中心病变患者提供了一种治疗选择。对于不能手术治疗或残留的CTEPH,球囊肺血管成形术和靶向药物治疗(如riociguat)开辟了新的治疗前景。讨论:CTEPH的诊断仍然是一个复杂的挑战。全科医生在反复出现呼吸困难、运动不耐受、右心衰迹象或肺栓塞后持续症状的患者中考虑CTEPH,并确保及时转诊到专门的肺动脉高压中心,具有关键作用。结论:CTEPH的早期诊断和循证管理可显著提高患者的生活质量和生存率。由于全科医生和内科医生处于第一线,他们的意识和教育对早期疾病识别至关重要。Orv Hetil. 2025;166(48): 1908 - 1915。
{"title":"[Chronic thromboembolic pulmonary hypertension - the hidden disease].","authors":"Gábor Kolodzey, László Balogh, Judit Barta, Andrea Péter, Tibor Szűk","doi":"10.1556/650.2025.33433","DOIUrl":"https://doi.org/10.1556/650.2025.33433","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but potentially curable form of pulmonary hypertension. Its pathophysiological background involves incomplete thrombus resolution following acute pulmonary embolism, in situ thrombosis, and vascular remodeling. An increase in pulmonary vascular resistance leads to persistent pulmonary hypertension, which, if left untreated, may progress to fatal right heart failure. CTEPH is often considered a \"hidden\" disease, as its nonspecific symptoms are frequently misattributed to other conditions.</p><p><strong>Objective: </strong>To provide an update overview of the epidemiology, pathophysiology, diagnostic challenges, and therapeutic options of CTEPH, with particular emphasis on the role of the general practitioners and the internists in early recognition.</p><p><strong>Method: </strong>A narrative literature review based on the 2022 ESC/ERS guidelines, the most recent European and international registries, and contemporary review.</p><p><strong>Results: </strong>The incidence of CTEPH following pulmonary embolism is estimated at 2-4%, although its true prevalence is likely higher. Diagnostic delays are common, with patients typically presenting to pulmonary hypertension centers 18-24 months after symptom onset. Pulmonary endarterectomy offers a curative treatment option for patients with surgically accessible central lesions. For inoperable or residual CTEPH, balloon pulmonary angioplasty and targeted pharmacological therapy, such as riociguat, have opened new therapeutic perspectives.</p><p><strong>Discussion: </strong>Diagnosis of CTEPH remains a complex challenge. General practitioners have a pivotal role by considering CTEPH in patients with recurrent dyspnea, exercise intolerance, signs of right heart failure, or persistent symptoms following pulmonary embolism, and by ensuring timely referral to specialized pulmonary hypertension centers.</p><p><strong>Conclusion: </strong>Early diagnosis and evidence-based management of CTEPH can significantly improve both quality of life and survival. As general practitioners and internists are on the frontline, their awareness and education are crucial for early disease recognition. Orv Hetil. 2025; 166(48): 1908-1915.</p>","PeriodicalId":19911,"journal":{"name":"Orvosi hetilap","volume":"166 48","pages":"1908-1915"},"PeriodicalIF":0.9,"publicationDate":"2025-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145637426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The role of the PNPLA3 gene rs738409 variant in the spectrum of metabolic dysfunction associated steatotic liver diseases]. [PNPLA3基因rs738409变异在代谢功能障碍相关脂肪变性肝病谱中的作用]。
IF 0.9 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-11-23 DOI: 10.1556/650.2025.33421
Ákos Nádasdi, Gábor Firneisz

Non-alcoholic fatty liver disease (NAFLD) - more recently referred to as metabolic dysfunction-associated steatotic liver disease (MASLD) - has become a widespread public health concern. Among the various factors contributing to its development and progression toward more severe forms (including steatohepatitis, liver fibrosis, cirrhosis, and hepatocellular carcinoma), a single nucleotide polymorphism in the PNPLA3 gene, resulting in an amino acid substitution, has emerged as one of the key genetic factors. Over the past two decades, this variant has been extensively studied. Current knowledge regarding both the clinical relevance of this variant and the role of its gene product in disease pathogenesis continues to expand, providing increasing insight into the physiological and pathological functions of PNPLA3 gene variants and their encoded protein isoforms. Although PNPLA3 genotyping is not yet part of routine diagnostics or therapeutic decision-making, the growing body of research and the variant's considerable effect size suggest potential future applications in prognostic assessment and therapeutic strategies - particularly within the framework of personalized medicine. The aim of this review is to provide a structured summary of the currently available published evidence, covering aspects of PNPLA3 functionality, biological mechanisms, clinical implications, and its potential utility in diagnostics, disease progression assessment, and therapeutic interventions. Orv Hetil. 2025; 166(47): 1843-1856.

非酒精性脂肪性肝病(NAFLD) -最近被称为代谢功能障碍相关脂肪性肝病(MASLD) -已成为一个广泛关注的公共卫生问题。在导致其发展和向更严重形式发展的各种因素中(包括脂肪性肝炎、肝纤维化、肝硬化和肝细胞癌),PNPLA3基因的单核苷酸多态性导致氨基酸替代,已成为关键遗传因素之一。在过去的二十年里,这种变异被广泛研究。目前关于该变异的临床相关性及其基因产物在疾病发病机制中的作用的知识不断扩大,为PNPLA3基因变异及其编码蛋白亚型的生理和病理功能提供了越来越多的见解。尽管PNPLA3基因分型尚未成为常规诊断或治疗决策的一部分,但越来越多的研究和该变异可观的效应量表明,未来在预后评估和治疗策略方面有潜在的应用,特别是在个性化医疗的框架内。本综述的目的是对目前可获得的已发表证据进行结构化总结,涵盖PNPLA3的功能、生物学机制、临床意义及其在诊断、疾病进展评估和治疗干预方面的潜在应用。Orv Hetil. 2025;166(47): 1843 - 1856。
{"title":"[The role of the PNPLA3 gene rs738409 variant in the spectrum of metabolic dysfunction associated steatotic liver diseases].","authors":"Ákos Nádasdi, Gábor Firneisz","doi":"10.1556/650.2025.33421","DOIUrl":"https://doi.org/10.1556/650.2025.33421","url":null,"abstract":"<p><p>Non-alcoholic fatty liver disease (NAFLD) - more recently referred to as metabolic dysfunction-associated steatotic liver disease (MASLD) - has become a widespread public health concern. Among the various factors contributing to its development and progression toward more severe forms (including steatohepatitis, liver fibrosis, cirrhosis, and hepatocellular carcinoma), a single nucleotide polymorphism in the PNPLA3 gene, resulting in an amino acid substitution, has emerged as one of the key genetic factors. Over the past two decades, this variant has been extensively studied. Current knowledge regarding both the clinical relevance of this variant and the role of its gene product in disease pathogenesis continues to expand, providing increasing insight into the physiological and pathological functions of PNPLA3 gene variants and their encoded protein isoforms. Although PNPLA3 genotyping is not yet part of routine diagnostics or therapeutic decision-making, the growing body of research and the variant's considerable effect size suggest potential future applications in prognostic assessment and therapeutic strategies - particularly within the framework of personalized medicine. The aim of this review is to provide a structured summary of the currently available published evidence, covering aspects of PNPLA3 functionality, biological mechanisms, clinical implications, and its potential utility in diagnostics, disease progression assessment, and therapeutic interventions. Orv Hetil. 2025; 166(47): 1843-1856.</p>","PeriodicalId":19911,"journal":{"name":"Orvosi hetilap","volume":"166 47","pages":"1843-1856"},"PeriodicalIF":0.9,"publicationDate":"2025-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145588286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[László Lampé, professor of obstetrics and gynecology died 5 years ago]. [László,妇产科教授,5年前去世]。
IF 0.9 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-11-23 DOI: 10.1556/650.2025.HO2843
Zoltán Papp, Zoltán Tóth
{"title":"[László Lampé, professor of obstetrics and gynecology died 5 years ago].","authors":"Zoltán Papp, Zoltán Tóth","doi":"10.1556/650.2025.HO2843","DOIUrl":"https://doi.org/10.1556/650.2025.HO2843","url":null,"abstract":"","PeriodicalId":19911,"journal":{"name":"Orvosi hetilap","volume":"166 47","pages":"1877-1883"},"PeriodicalIF":0.9,"publicationDate":"2025-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145588359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The role of artificial intelligence in the design and feasibility of early-phase oncology clinical trials]. 【人工智能在早期肿瘤临床试验设计和可行性中的作用】。
IF 0.9 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-11-23 DOI: 10.1556/650.2025.33420
Patrik Pollák, Szabolcs Barótfi, Ildikó Csóka, Mária Budai-Szűcs

Oncology clinical trials play a pivotal role in the development of new therapeutic options; however, their implementation remains an extremely costly and time-consuming process. Artificial intelligence can open new horizons in the design and conduct of clinical trials, particularly in early phases, where safety, dose planning, and patient recruitment efficiency are critical. This paper aims to explore the potential applications of artificial intelligence in various stages of early-phase oncology trials, including biostatistical design, patient enrollment, and quality assurance aspects. Based on case studies and examples from the literature, it can be concluded that artificial intelligence can assist with precise protocol design, shorten recruitment timelines, and improve predictive performance in dose planning and patient selection, thereby reducing the number of adverse events. At the same time, regulatory, ethical, and data protection challenges remain significant barriers to the widespread adoption of artificial intelligence. Integrating artificial intelligence into clinical trials requires not only technological but also strategic-level modernization, from the industrial companies and authorities as well. The reliable and validated application of artificial intelligence could represent a major advancement in clinical research, particularly in increasing the success rate of early-phase trials. Orv Hetil. 2025; 166(47): 1857-1868.

肿瘤临床试验在开发新的治疗方案中发挥着关键作用;然而,它们的实施仍然是一个极其昂贵和耗时的过程。人工智能可以为临床试验的设计和实施开辟新的视野,特别是在安全性、剂量计划和患者招募效率至关重要的早期阶段。本文旨在探讨人工智能在早期肿瘤试验各个阶段的潜在应用,包括生物统计学设计、患者入组和质量保证方面。根据案例研究和文献中的例子,可以得出结论,人工智能可以帮助精确的方案设计,缩短招募时间表,提高剂量计划和患者选择的预测性能,从而减少不良事件的数量。与此同时,监管、道德和数据保护方面的挑战仍然是人工智能广泛应用的重大障碍。将人工智能整合到临床试验中,不仅需要技术层面的现代化,还需要来自工业公司和当局的战略层面的现代化。人工智能的可靠和有效应用可能代表着临床研究的重大进步,特别是在提高早期试验的成功率方面。Orv Hetil. 2025;166(47): 1857 - 1868。
{"title":"[The role of artificial intelligence in the design and feasibility of early-phase oncology clinical trials].","authors":"Patrik Pollák, Szabolcs Barótfi, Ildikó Csóka, Mária Budai-Szűcs","doi":"10.1556/650.2025.33420","DOIUrl":"10.1556/650.2025.33420","url":null,"abstract":"<p><p>Oncology clinical trials play a pivotal role in the development of new therapeutic options; however, their implementation remains an extremely costly and time-consuming process. Artificial intelligence can open new horizons in the design and conduct of clinical trials, particularly in early phases, where safety, dose planning, and patient recruitment efficiency are critical. This paper aims to explore the potential applications of artificial intelligence in various stages of early-phase oncology trials, including biostatistical design, patient enrollment, and quality assurance aspects. Based on case studies and examples from the literature, it can be concluded that artificial intelligence can assist with precise protocol design, shorten recruitment timelines, and improve predictive performance in dose planning and patient selection, thereby reducing the number of adverse events. At the same time, regulatory, ethical, and data protection challenges remain significant barriers to the widespread adoption of artificial intelligence. Integrating artificial intelligence into clinical trials requires not only technological but also strategic-level modernization, from the industrial companies and authorities as well. The reliable and validated application of artificial intelligence could represent a major advancement in clinical research, particularly in increasing the success rate of early-phase trials. Orv Hetil. 2025; 166(47): 1857-1868.</p>","PeriodicalId":19911,"journal":{"name":"Orvosi hetilap","volume":"166 47","pages":"1857-1868"},"PeriodicalIF":0.9,"publicationDate":"2025-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145588369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The Hungarian Neonatal Hearing Screening Registry: insights from five years of operation]. [匈牙利新生儿听力筛查登记:来自5年手术的见解]。
IF 0.9 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-11-23 DOI: 10.1556/650.2025.33426
Anita Gáborján, Miklós Szabó, Gábor Katona, Béla Muzsik

Introduction: Newborn hearing screening plays a crucial role in the early detection and treatment of hearing loss.

Objective: This study presents a database developed by Hungarian software engineers, designed for the collection and analysis of data on hearing screening and subsequent care. The National Newborn Hearing Screening Registry has been collecting data since September 1, 2019, on mandatory objective hearing screening conducted in neonatal units and neonatal intensive care centres, along with confirmations from five designated verification centres. The aim of the study is to describe the structure of the database and to analyze the data collected.

Method: The registry aggregates data from screening devices performing brainstem-evoked response audiometry (BERA) via machine-to-machine communication. Indicators were defined and analyzed using registry data collected over a five-year period (2020-2024) and evaluated annually.

Results: During the study period, hearing screening data for a total of 345,945 newborns were recorded in the database. According to the registry data, screening coverage was 80.16%. Among screened newborns, 6.14% were referred due to suspected hearing loss. Only 16.81% of those who had a positive screening result underwent audiological evaluation at a verification centre, according to the transferred data.

Discussion: Data reported to the registry indicate that newborn hearing screening is not yet comprehensive. The high rate of suspected cases places an increased burden on the health care system and affected families. There is a low rate of data transfer to verification centres, raising concerns regarding access to adequate audiological diagnostics and treatment for screened children.

Conclusion: These findings underscore the importance of standardized data collection for effective hearing rehabilitation. The results provide insight into care pathways and highlight critical deficiencies in the system that require improvement. Data collection alone is insufficient; continuous data and patient follow-up are essential. Enhancing the involvement and awareness of health visitors and pediatricians is also key, which constitutes one of the main objectives of this study. Orv Hetil. 2025; 166(47): 1869-1876.

新生儿听力筛查在听力损失的早期发现和治疗中起着至关重要的作用。目的:本研究介绍了一个由匈牙利软件工程师开发的数据库,旨在收集和分析听力筛查和后续护理的数据。自2019年9月1日以来,国家新生儿听力筛查登记处一直在收集新生儿病房和新生儿重症监护中心进行的强制性客观听力筛查的数据,以及五个指定验证中心的确认。本研究的目的是描述数据库的结构并分析收集到的数据。方法:该注册表通过机器对机器通信收集来自执行脑干诱发反应听力学(BERA)的筛选设备的数据。使用五年期(2020-2024年)收集的登记数据定义和分析指标,并每年进行评估。结果:在研究期间,数据库共记录了345,945名新生儿的听力筛查数据。根据注册数据,筛查覆盖率为80.16%。在筛查的新生儿中,6.14%因疑似听力损失而转诊。根据转移的数据,只有16.81%的筛查结果呈阳性的人在验证中心接受了听力学评估。讨论:向登记处报告的数据表明,新生儿听力筛查尚不全面。高疑似病例率增加了卫生保健系统和受影响家庭的负担。向核查中心传送数据的比率很低,这引起人们对接受筛查的儿童能否获得适当的听力学诊断和治疗的关切。结论:这些发现强调了标准化数据收集对有效听力康复的重要性。研究结果提供了对护理途径的洞察,并突出了系统中需要改进的关键缺陷。仅收集数据是不够的;持续的数据和患者随访是必不可少的。加强保健访视员和儿科医生的参与和认识也是关键,这是本研究的主要目标之一。Orv Hetil. 2025;166(47): 1869 - 1876。
{"title":"[The Hungarian Neonatal Hearing Screening Registry: insights from five years of operation].","authors":"Anita Gáborján, Miklós Szabó, Gábor Katona, Béla Muzsik","doi":"10.1556/650.2025.33426","DOIUrl":"https://doi.org/10.1556/650.2025.33426","url":null,"abstract":"<p><strong>Introduction: </strong>Newborn hearing screening plays a crucial role in the early detection and treatment of hearing loss.</p><p><strong>Objective: </strong>This study presents a database developed by Hungarian software engineers, designed for the collection and analysis of data on hearing screening and subsequent care. The National Newborn Hearing Screening Registry has been collecting data since September 1, 2019, on mandatory objective hearing screening conducted in neonatal units and neonatal intensive care centres, along with confirmations from five designated verification centres. The aim of the study is to describe the structure of the database and to analyze the data collected.</p><p><strong>Method: </strong>The registry aggregates data from screening devices performing brainstem-evoked response audiometry (BERA) via machine-to-machine communication. Indicators were defined and analyzed using registry data collected over a five-year period (2020-2024) and evaluated annually.</p><p><strong>Results: </strong>During the study period, hearing screening data for a total of 345,945 newborns were recorded in the database. According to the registry data, screening coverage was 80.16%. Among screened newborns, 6.14% were referred due to suspected hearing loss. Only 16.81% of those who had a positive screening result underwent audiological evaluation at a verification centre, according to the transferred data.</p><p><strong>Discussion: </strong>Data reported to the registry indicate that newborn hearing screening is not yet comprehensive. The high rate of suspected cases places an increased burden on the health care system and affected families. There is a low rate of data transfer to verification centres, raising concerns regarding access to adequate audiological diagnostics and treatment for screened children.</p><p><strong>Conclusion: </strong>These findings underscore the importance of standardized data collection for effective hearing rehabilitation. The results provide insight into care pathways and highlight critical deficiencies in the system that require improvement. Data collection alone is insufficient; continuous data and patient follow-up are essential. Enhancing the involvement and awareness of health visitors and pediatricians is also key, which constitutes one of the main objectives of this study. Orv Hetil. 2025; 166(47): 1869-1876.</p>","PeriodicalId":19911,"journal":{"name":"Orvosi hetilap","volume":"166 47","pages":"1869-1876"},"PeriodicalIF":0.9,"publicationDate":"2025-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145588372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Management of staple line leak after sleeve gastrectomy using endoscopic suturing and stent placement]. 套筒胃切除术后钉线漏的内镜缝合及支架置入术处理。
IF 0.9 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-11-16 DOI: 10.1556/650.2025.33402
Gábor Barcsák, Timothy Jackson, Intekhab Hossain, Viktor Reich, András Botond Fecső

Sleeve gastrectomy has been the most commonly performed metabolic surgical procedure in recent years. One of its rare but serious postoperative complications is staple line leak. Due to the high intraluminal pressure within the gastric sleeve, its management is technically challenging. Over time, treatment strategies have shifted from surgical approaches toward interventional radiologic and endoscopic techniques. In this case report, we present a 37-year-old female patient who underwent sleeve gastrectomy for morbid obesity. Postoperatively, she developed abdominal symptoms prompting a CT scan, which initially revealed a perigastric hematoma. This was drained by interventional radiology. Following drain removal and a brief period of clinical improvement, her symptoms recurred. A repeat CT scan demonstrated contrast extravasation and a collection adjacent to the staple line. A new percutaneous drain was inserted via interventional radiology. She was then referred to our bariatric unit, where the defect was definitively closed using endoscopic suturing system under general anesthesia, followed by placement of a self-expanding metal stent. The stent was well tolerated, with no migration. After 5 weeks, it was successfully removed. A subsequent CT scan showed no further contrast leak. The patient is currently asymptomatic, satisfied with her weight loss trajectory and quality of life. This case highlights that the management of staple line leaks after sleeve gastrectomy has evolved, with less invasive methods – such as interventional radiology and endoscopy – and their combination now playing a central role in treatment. Orv Hetil. 2025; 166(46): 1827–1832.

袖式胃切除术是近年来最常用的代谢外科手术。其中一个罕见但严重的术后并发症是钉线泄漏。由于胃套内腔内压力高,其处理在技术上具有挑战性。随着时间的推移,治疗策略已经从手术方法转向介入放射和内窥镜技术。在这个病例报告中,我们报告了一位37岁的女性患者,她因病态肥胖而接受了袖式胃切除术。术后,她出现腹部症状,促使CT扫描,最初发现腹壁血肿。这是由介入放射学排出的。引流管移除及短暂的临床改善后,患者症状复发。重复CT扫描显示造影剂外渗,并在钉线附近聚集。通过介入放射学插入新的经皮引流管。然后她被转到我们的减肥单位,在全麻下使用内窥镜缝合系统彻底关闭缺损,随后放置一个自膨胀的金属支架。支架耐受性良好,无移位。5周后,成功摘除。随后的CT扫描显示没有进一步的造影剂泄漏。患者目前无症状,对她的减肥轨迹和生活质量感到满意。这个病例强调了袖式胃切除术后钉线渗漏的处理已经发展,侵入性更小的方法,如介入放射学和内窥镜检查,以及它们的结合现在在治疗中起着核心作用。Orv Hetil. 2025;166(46): 1827 - 1832。
{"title":"[Management of staple line leak after sleeve gastrectomy using endoscopic suturing and stent placement].","authors":"Gábor Barcsák, Timothy Jackson, Intekhab Hossain, Viktor Reich, András Botond Fecső","doi":"10.1556/650.2025.33402","DOIUrl":"10.1556/650.2025.33402","url":null,"abstract":"<p><p>Sleeve gastrectomy has been the most commonly performed metabolic surgical procedure in recent years. One of its rare but serious postoperative complications is staple line leak. Due to the high intraluminal pressure within the gastric sleeve, its management is technically challenging. Over time, treatment strategies have shifted from surgical approaches toward interventional radiologic and endoscopic techniques. In this case report, we present a 37-year-old female patient who underwent sleeve gastrectomy for morbid obesity. Postoperatively, she developed abdominal symptoms prompting a CT scan, which initially revealed a perigastric hematoma. This was drained by interventional radiology. Following drain removal and a brief period of clinical improvement, her symptoms recurred. A repeat CT scan demonstrated contrast extravasation and a collection adjacent to the staple line. A new percutaneous drain was inserted via interventional radiology. She was then referred to our bariatric unit, where the defect was definitively closed using endoscopic suturing system under general anesthesia, followed by placement of a self-expanding metal stent. The stent was well tolerated, with no migration. After 5 weeks, it was successfully removed. A subsequent CT scan showed no further contrast leak. The patient is currently asymptomatic, satisfied with her weight loss trajectory and quality of life. This case highlights that the management of staple line leaks after sleeve gastrectomy has evolved, with less invasive methods – such as interventional radiology and endoscopy – and their combination now playing a central role in treatment. Orv Hetil. 2025; 166(46): 1827–1832.</p>","PeriodicalId":19911,"journal":{"name":"Orvosi hetilap","volume":"166 46","pages":"1827-1832"},"PeriodicalIF":0.9,"publicationDate":"2025-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145530561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Prevalence and correlates of indoor smoking bans on traditional tobacco use in Hungary in 2009 and 2022]. [2009年和2022年匈牙利室内禁止传统烟草使用的流行情况及其相关因素]。
IF 0.9 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-11-16 DOI: 10.1556/650.2025.33410
Zoltán Brys, Edit Paulik, Fruzsina Albert, Melinda Pénzes

Introduction: Voluntary bans on smoking inside the home reduce exposure to secondhand smoke, prevent smoking uptake, and support cessation. In Hungary, limited data are available on the temporal changes and correlates of smoke-free household rules. Objective: To examine the prevalence, temporal trend, and sociodemographic correlates of voluntary bans on traditional tobacco smoking inside the home. Method: We conducted a secondary analysis of data from two surveys in 2009 and one in 2022. The unit of analysis was the household. We applied Z-tests, Cochran–Armitage trend tests, and binomial logistic regression with calculation of average marginal effects (AMEs). Results: The proportion of households with a complete ban on smoking inside the home increased in Hungary from 60.6% in 2009 to 75.1% in 2022 (h = 0.3; p<0.01). Nevertheless, in 2022, 25.2% (95% CI: 22.5–28.0%) of children under the age of 18 still lived in households where smoking inside the home was allowed. Financial difficulties (AME ≈ –0.09 to –0.01) and the presence of a smoker in the household (AME ≈ –0.42 to –0.30) had a negative association in all models. The presence of a child under 18 years slightly increased the likelihood of a complete ban (AME ≈ 0.02 to 0.10). Discussion: Although there has been improvement, minors are still not adequately protected from indoor tobacco smoke in all Hungarian households. Conclusion: Our findings highlight the need for targeted health communication and intervention programmes, particularly among disadvantaged households with children and at least one smoker. Orv Hetil. 2025; 166(46): 1818–1826.

导言:在家中自愿禁止吸烟可减少二手烟暴露,防止吸烟,并支持戒烟。在匈牙利,关于家庭无烟规定的时间变化和相关关系的数据有限。目的:研究家庭内自愿禁止传统吸烟的流行程度、时间趋势和社会人口学相关性。方法:对2009年两次调查和2022年一次调查的数据进行二次分析。分析的单位是家庭。我们应用z检验、Cochran-Armitage趋势检验和二项逻辑回归计算平均边际效应(AMEs)。结果:匈牙利完全禁止室内吸烟的家庭比例从2009年的60.6%增加到2022年的75.1% (h = 0.3; p
{"title":"[Prevalence and correlates of indoor smoking bans on traditional tobacco use in Hungary in 2009 and 2022].","authors":"Zoltán Brys, Edit Paulik, Fruzsina Albert, Melinda Pénzes","doi":"10.1556/650.2025.33410","DOIUrl":"10.1556/650.2025.33410","url":null,"abstract":"<p><p>Introduction: Voluntary bans on smoking inside the home reduce exposure to secondhand smoke, prevent smoking uptake, and support cessation. In Hungary, limited data are available on the temporal changes and correlates of smoke-free household rules. Objective: To examine the prevalence, temporal trend, and sociodemographic correlates of voluntary bans on traditional tobacco smoking inside the home. Method: We conducted a secondary analysis of data from two surveys in 2009 and one in 2022. The unit of analysis was the household. We applied Z-tests, Cochran–Armitage trend tests, and binomial logistic regression with calculation of average marginal effects (AMEs). Results: The proportion of households with a complete ban on smoking inside the home increased in Hungary from 60.6% in 2009 to 75.1% in 2022 (h = 0.3; p<0.01). Nevertheless, in 2022, 25.2% (95% CI: 22.5–28.0%) of children under the age of 18 still lived in households where smoking inside the home was allowed. Financial difficulties (AME ≈ –0.09 to –0.01) and the presence of a smoker in the household (AME ≈ –0.42 to –0.30) had a negative association in all models. The presence of a child under 18 years slightly increased the likelihood of a complete ban (AME ≈ 0.02 to 0.10). Discussion: Although there has been improvement, minors are still not adequately protected from indoor tobacco smoke in all Hungarian households. Conclusion: Our findings highlight the need for targeted health communication and intervention programmes, particularly among disadvantaged households with children and at least one smoker. Orv Hetil. 2025; 166(46): 1818–1826.</p>","PeriodicalId":19911,"journal":{"name":"Orvosi hetilap","volume":"166 46","pages":"1818-1826"},"PeriodicalIF":0.9,"publicationDate":"2025-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145530520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dr. Meskó Bertalan: Térkép a jövőhöz – Jövőkutatás mindenkinek, Partvonal Kiadó, Budapest, 2025.
IF 0.9 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-11-16 DOI: 10.1556/650.2025.46M
Tamás Kristóf, Péter Schmidt
{"title":"Dr. Meskó Bertalan: Térkép a jövőhöz – Jövőkutatás mindenkinek, Partvonal Kiadó, Budapest, 2025.","authors":"Tamás Kristóf, Péter Schmidt","doi":"10.1556/650.2025.46M","DOIUrl":"10.1556/650.2025.46M","url":null,"abstract":"","PeriodicalId":19911,"journal":{"name":"Orvosi hetilap","volume":"166 46","pages":"1839-1840"},"PeriodicalIF":0.9,"publicationDate":"2025-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145530727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Orvosi hetilap
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1